secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001654954-24-006131
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling
-----------------------------------------------------------------------------

- Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.
- Cash $12.5M; raised ~$8.0M net in Feb 2024 public offering.
- Phase 3 LEVEL study for PH-HFpEF enrolling; 24 sites initiated, 152 patients planned.
- Secured global development/commercial rights to levosimendan in PH-HFpEF; new patent issued (US 11,969,424).
- Topline data from LEVEL expected second half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/0001654954-24-006131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-006131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer